A Phase II Trial of Gefitinib Monotherapy in Chemotherapy-Naïve Patients of 75 Years or Older with Advanced Non-small Cell Lung Cancer-Reference-Cited by-同舟云学术

A Phase II Trial of Gefitinib Monotherapy in Chemotherapy-Naïve Patients of 75 Years or Older with Advanced Non-small Cell Lung Cancer

Published:2008-10 Issue:10 Volume:3 Page:1166-1171
ISSN:1556-0864
Container-title:Journal of Thoracic Oncology
language:en
Short-container-title:Journal of Thoracic Oncology

Author:

Ebi Noriyuki,Semba Hiroshi,Tokunaga Sho j i,Takayama Koichi,Wataya Hiroshi,Kuraki Takashige,Yamamoto Hidehiko,Akamine Shin j i,Okamoto Isamu,Nakanishi Yoichi

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Oncology

Reference29 articles.

1. Global cancer statistics in the year 2000;Parkin;Lancet Oncol,2001

2. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomized clinical trials;BMJ,1995

3. Comparison of four chemotherapy regimens for advanced non-small cell lung cancer;Schiller;N Engl J Med,2002

4. Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small cell lung cancer: four-arm cooperative study in Japan;Ohe;Ann Oncol,2007

Cited by 41 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Overall survival of super-elderly (85 years or older) advanced non-small cell lung cancer patients with active epidermal growth factor receptor mutations receiving first-line gefitinib therapy: a single-institute retrospective study;Journal of Cancer Research and Clinical Oncology;2020-08-06

2. Fatal toxic effects related to EGFR tyrosine kinase inhibitors based on 53 cohorts with 9,569 participants;Journal of Thoracic Disease;2020-08

3. Pneumonitis in advanced non-small-cell lung cancer patients treated with EGFR tyrosine kinase inhibitor: Meta-analysis of 153 cohorts with 15,713 patients;Lung Cancer;2018-09

4. Current and Emerging Options in the Management of EGFR Mutation-Positive Non-Small-Cell Lung Cancer: Considerations in the Elderly;Drugs & Aging;2015-10-07

5. First-line gefitinib treatment in elderly patients (aged ≥75 years) with non-small cell lung cancer harboring EGFR mutations;Cancer Chemotherapy and Pharmacology;2015-08-08